Bluephage is awarded the ACCIÓ prize by the Paris office for the best proposal in the field of health sciences
Bluephage, a spin-off of the University of Barcelona dedicated to the development and marketing of solutions for the control of water safety and quality using microbiological indicators (bacteriophages), has been awarded the ACCIÓ prize by the Paris office for the best proposal in the field of health sciences. Bluephage’s product portfolio addresses the needs of water management in France, where there is already legislation in place to assess bacteriophages in one type of waters. “This award is a recognition of our business project and provides an opportunity to facilitate the entry of Bluephage’s products into the French market”, said Anicet Blanch, professor at the University of Barcelona and co-founder of Bluepahage.
This spin-off was also one of the seven finalist companies in the Life and Health Sciences category of the 23rd ACCIÓ Investment Forum, which brought together 21 start-ups in search of funding. In addition, Bluephage has been invited to the Keiretsu Forum, a meeting of an international network of investors that will take place on 19 July at the Barcelona Stock Exchange. “Participation in this Forum will allow us to present the company to an audience of investors who can consider participating in the second round of financing opened this July,” says Blanch.
Bluephage is currently closing the product development phase, and is in the process of industrializing and starting to market its products within the European region. At the same time, it is initiating the validation of its products through standardisation agencies.